Jonathan G. Drachman - Aug 2, 2022 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NLTX)

Role
President and CEO, Director
Signature
/s/ Sean Smith, Attorney-in-Fact for Jonathan G. Drachman
Stock symbol
NLTX
Transactions as of
Aug 2, 2022
Transactions value $
$0
Form type
4
Date filed
8/4/2022, 04:38 PM
Previous filing
Jun 24, 2022
Next filing
Jun 23, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NLTX Stock Option (Right to Buy) Award $0 +350K $0.00 350K Aug 2, 2022 Common Stock 350K $0.99 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/4 of the total shares on August 2, 2023, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.